<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="750">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097107</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.15.001.04</org_study_id>
    <nct_id>NCT03097107</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Discovery DMCC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Discovery DMCC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients
      with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARO.15.001.04 is a multicenter, prospective, randomized, double-blind, placebo-controlled,
      parallel arm, 12-week study designed to evaluate the safety and efficacy of Saroglitazar
      Magnesium 1, 2 and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.

      A total 124 subjects will be enrolled in a ratio of 1:1:1:1 to receive either Saroglitazar
      Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">April 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in triglyceride cholesterol levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage change in triglyceride cholesterol levels from baseline to Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in TG-C</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Percentage change from baseline to Week 4 and 8 in TG-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in lipid profile.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage change from baseline to 12 in lipid profile.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 1 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 2 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 4 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults subjects (≥18 year) of either gender.

          2. Average fasting TG-C ≥500 mg/dL and ≤1500 mg/dL (from Visits 2 and 2.1).

          3. Able and willing to give written informed consent and comply with the requirements of
             the study protocol.

        Exclusion Criteria:

          1. History of pancreatitis within 6 months of the initial screening visit (V1); patients
             that have an episode of pancreatitis after V1, but before randomization will not be
             randomized.

          2. History of &gt;5% weight gain or weight loss or participation in weight gain/loss
             program in past 6 months and not in the maintenance phase as of Visit 1 (V1).

          3. Diabetic (as per ADA guideline) subject with HbA1c ≥9.5%.

          4. Subjects on insulin, GLP-1 agonists, or DPP-4 inhibitors, SGLT 2 inhibitors,
             pramlintide, thiazolidinediones (TZDs) or glitazars 3 months prior to Visit 1 (V1).

          5. Subjects on anti-obesity medications within 6 months of screening. (i.e. orlistat,
             lorcaserin, phentermine, naltrexone etc.).

          6. Subjects on drugs that may promote weight loss (i.e. anti-epileptic agents such as
             topiramate, zonisamide and the anti-depressant bupropion) may not be taken, unless
             the dose is stable for 3 months and the indication for use is not weight loss.

          7. Subjects on nutraceutical supplements within 3 months of Visit 1 (Refer Annexure 1).

          8. Subjects with unexplained hematuria prior to or first noted during screening.

          9. Subjects with anemia who are undergoing repletion of deficiencies (iron, folate, B12)
             not in the maintenance phase as of Visit 1 (V1).

         10. Subjects on concomitant lipid-lowering medications and not willing to participate in
             Lead-in/Run-in Phase (Please refer Lead-in/Run-in Phase).

         11. Subjects having heart failure of NYHA class (III-IV), unstable angina, Acute
             Myocardial Infarction, Stroke, Transient ischaemic attack, any coronary
             revascularisation procedure and hospitalization for acute coronary syndrome and
             discharge within 6 months prior to screening.

         12. Patients with Left Ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF)
             &lt;40%, as measured through ECHO)

         13. Uncontrolled hypertension (SBP &gt;160 and/or DBP&gt;100).

         14. An uncontrolled thyroid disorder

               -  Uncontrolled hyperthyroidism is defined as any history of hyperthyroidism that
                  has either not been treated with either radioactive iodine (RAI) and/or surgery
                  -or- that has been treated with RAI and/or surgery, but has required ongoing
                  continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e.
                  methimazole or proplythiouracil) within 6 months of V1

               -  Uncontrolled hypothyroidism is defined as initiation of thyroid hormone
                  replacement therapy or dose adjustment of replacement therapy within 3 months of
                  V1.

         15. History of GI malabsorption or history of gastric bypass, banding, or diversional
             bariatric surgery.

         16. History of active liver disease or gall stones or hepatic dysfunction demonstrated by
             AST and ALT ≥2 times of upper normal limit (UNL) or bilirubin ≥1.5 times UNL at
             Screening visit (V1).

         17. History of myopathies or evidence of active muscle diseases demonstrated by CPK ≥5
             times UNL at Screening visit.

         18. History of any other concurrent serious illness or malignancy (except successfully
             treated basal and squamous cell carcinoma of the skin) within the past 5 years (e.g.
             tuberculosis, HIV).

         19. Positive HIV, hepatitis A, hepatitis B, or hepatitis C at screening.

         20. History of excessive consumption of alcoholic beverages (consumes &gt;2 alcoholic drinks
             per day or &gt;14 alcoholic drinks per week, or engages in binge drinking). For the
             remainder of the study, subjects should agree to refrain from excessive alcohol
             consumption (i.e., &gt;2 alcoholic beverages per day), to maintain their current dietary
             regimen, and to not alter their normal activity routines. (Note: Patient should not
             drink alcohol 24 hrs prior to site visit).

         21. History of known allergy, sensitivity or intolerance to the study drugs and their
             formulation ingredients.

         22. Renal dysfunction demonstrated by eGFR&lt;50 mL/min/1.73 m2.

         23. History of clinically significant* systemic steroid therapy (intramuscular,
             intravenous, intra-articular, or oral route) within 3 months of the screening visit
             (V1) or anticipated requirement for systemic steroid therapy at V1 (however, topical,
             ophthalmic and inhaled steroids are allowed).

             *Clinically significant' (i.e. no more than 5 days of systemic steroids treatment
             within 3 months of V1)

         24. History of long term continuous (i.e. for greater than 3 months using a minimum of 4
             days per week) use of non-steroidal anti-inflammatory drugs for any treatment such as
             osteoarthritis, rheumatoid arthritis etc.

         25. Participation in any other clinical trial in the past 3 months.

         26. Subjects who have donated / received blood within 3 months of screening.

         27. Pregnancy (including a positive serum pregnancy test at Visit 1), lactation or
             planned pregnancy/lactation during any time during the study or follow-up period.

         28. Subjects with hormonal contraceptives / hormone replacement therapy.

         29. Women of childbearing potential (WOCBP) and men, UNLESS using effective contraceptive
             methods, such as an intra uterine device or other mechanical contraception method
             with condom or diaphragm and spermicide) throughout the study. For male patients,
             contraception measures (condom and spermicide) must be taken during the study, either
             by the male participant or his female partner. (Note: Enrolled females otherwise must
             be surgically sterilized for at least the 6 months preceding Visit 1 or
             postmenopausal, defined as 12 months with no menses without an alternative medical
             cause).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vimal Sanghavi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Discovery DMCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vimal Sanghavi, MD</last_name>
    <phone>971 43998280</phone>
    <email>vimal.sanghavi@zydusdiscovery.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deven V Parmar, MD</last_name>
    <phone>9179665555</phone>
    <phone_ext>580</phone_ext>
    <email>Deven.Parmar@zyduscadila.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Lipetz, DO</last_name>
    </contact>
    <investigator>
      <last_name>Robert Lipetz, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alon Steinberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alon Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Health Partners</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kari Uusinarkaus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kari Uusinarkaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Bradenton</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Lakeland</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oviedo Medical Research, LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley Block, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bradley Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Huffman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cynthia Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance LLC</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raymond Tidman</last_name>
    </contact>
    <investigator>
      <last_name>Raymond Tidman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drug Studies America</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herman Clinical Research, LLC</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lee Herman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lee Herman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danny Sugimoto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Danny Sugimoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Glover, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Glover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tana Goering, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tana Goering, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Miller, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Geller</last_name>
    </contact>
    <investigator>
      <last_name>Steven Geller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Medical Research</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Pullman</last_name>
    </contact>
    <investigator>
      <last_name>John Pullman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Montgomery, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Montgomery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian R Webster, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brian R Webster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Traci Turner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Traci Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Padma Mangu</last_name>
    </contact>
    <investigator>
      <last_name>Padma Mangu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wells Institute for Health Awareness</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Letitia Thompson-Hargrave, DO</last_name>
    </contact>
    <investigator>
      <last_name>Letitia Thompson-Hargrave, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research - Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terence Isakov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Terence Isakov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Awasty Research Network, LLC</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivek Awasty, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivek Awasty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research, LLC - Willoughby Hills</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Bertsch, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Bertsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Research Group, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Azorr</last_name>
    </contact>
    <investigator>
      <last_name>Michael Azorr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederick A Martin</last_name>
    </contact>
    <investigator>
      <last_name>Frederick A Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Velazquez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Velazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James McKenney, PharmD</last_name>
    </contact>
    <investigator>
      <last_name>James McKenney, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>March 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>saroglitazar magnesium</keyword>
  <keyword>lipid disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>See above.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
